C ell-based therapy is emerging as a potential new therapeutic strategy that as an adjunct to revascularization could offer additional clinical benefits 1 by virtue of producing both structural and functional cardiac improvements. There is a particular interest in testing the impact of delivering bone marrow-derived stem cells during CABG, and accumulating studies [2] [3] [4] [5] suggest that the improvement in several functional indices is greater than that achieved with CABG alone.
Editorial, see p 1222
Preclinical studies provide evidence that bone marrow stem cells contribute to cardiac function and reverse remodeling after ischemic damage 6 acting both locally 7, 8 and remotely (possibly through paracrine mechanisms). [9] [10] [11] There seem to be ≥3 dominant mechanisms that underlie the cardiac reparative response: reduction in tissue fibrosis, neovascularization, and neomyogenesis. One critical question that emerges from the deployment of MSCs during CABG relates to the mechanisms responsible for the MSC-induced effects, an issue with major clinical implications in terms of where and how the cells should be administered during cardiac surgical revascularization.
In studies to date, investigators have either infused 12 or injected 2, 3 bone marrow-derived cells in areas that were undergoing revascularization. This strategy, although rational, has not allowed the detection of cell mechanisms of action that are independent of revascularization. Although the reported benefits can thus be attributed to a potential synergy 13 between the favorable environment created by the revascularization of the region and the MSCs, the precise delineation of each contribution, however, remains unknown.
Here, we test the hypothesis that intramyocardial injections of autologous MSCs delivered to segments of myocardium not receiving surgical revascularization improve regional cardiac structure and function. Our study design stipulated that cells would be injected in areas deemed unfit for revascularization to test the hypothesis that MSCs act both independently of revascularization and as an adjunct to CABG. Moreover this trial used cardiac MRI imaging that permitted direct measurement of the phenotype of functional and anatomic restitution observed after MSCs delivery. This trial, which originally was designed to enroll 45 patients, was suspended after 9 patients were enrolled because of slow accrual. Here, we present the comprehensive cardiac phenotypic data obtained from the 6 enrolled subjects that received MSCs during CABG surgery.
Methods
Eligible patients had a diagnosis of chronic ischemic left ventricular (LV) dysfunction secondary to MI and were scheduled to undergo CABG. The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial was approved by the institutional review boards of the University of Miami Miller School of Medicine, The Johns Hopkins University School of Medicine, and the Miami Veterans Affairs Hospital; all patients gave written informed consent. Patients underwent bone marrow aspiration from the iliac crest, isolation, and expansion of MSCs.
14-17 MSC characterization is summarized in the Online Table  I . After randomization, MSCs were transepicardially delivered, under direct visualization, using a syringe and 25-gauge needle after the completion of the CABG procedure in areas of the myocardium not deemed fit for surgical revascularization.
Cardiac MRI for structure and function was performed at baseline, at 3, 6, and 18 months after the product delivery. Global and regional measurements 18 were made for all time points, and the results were grouped based on whether LV areas that contained scar received injections of MSCs alone in the absence of revascularization (injected only) were only revascularized but not injected with MSCs (revascularized only) or received neither revascularization nor MSCs (untreated). Detailed regional MRI studies included (1) delayed contrast-enhancement, (2) first pass perfusion, (3) end-diastolic wall thickness, (4) end systolic wall thickening, (5) peak systolic circumferential strain, (6) peak diastolic strain rate, 19 and (7) topographical analyses 20 of the injected infarcted areas. A concordance index score (CIS) was devised to investigate the phenotype of recovery in response to stem cell therapy. Five MRI variables were chosen to reflect the biology of the 3 proposed 17 mechanisms with which MSCs exert their effects: (1) antifibrotic 21 effects were measured by using delayed contrast-enhancement images, (2) proangiogenic 22 effects were quantified by first pass perfusion, and (3) regenerative effects 9, 23 that lead to restoration of contractile function were measured by using end diastolic wall thickness, end systolic thickening, and tagged images (circumferential strain). Improvement compared with baseline was graded with 1 point and deterioration with −1, whereas no change (±5%) was graded with zero points. Accordingly, in each segment a cumulative score was calculated by adding the points graded for changes in (1) infarct size, (2) perfusion at rest, and (3) the average of the points for changes in end diastolic wall thickness, systolic thickening, and circumferential strain. A concordant improvement in all 5 variables yielded a cumulative CIS of 3 points, whereas a deterioration in all variables, a score of −3 points.
An expanded Methods section is available in the Online Data Supplement.
Results

Demographic and Perioperative Data
Preoperative baseline characteristics of the patients are summarized in Table 1 , and their medication at entry as well as at 18 months are shown in the Online Table II . Six patients were enrolled and randomized to the MSC group (2 injected with the low dose and 4 with the higher dose). All patients were men with average age of 54.9 years and had hypertension and hyperlipidemia, 83.3% were smokers, 2 had a history of congestive heart failure, and all were in New York Heart Association functional class I/II. The average time between last MI and the time of study enrollment was 675 days (range 70-1565 days). An average of 3±0.3 coronary arteries were grafted (range 2-4). All patients received a left internal thoracic artery graft anastomosed to the left anterior descending coronary artery. One patient received bilateral internal mammary artery grafts. Ten venous grafts were used to graft right coronary arteries, left circumflex arteries, and diagonal branches. The median number of stem cell injections was 10 (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , for a total volume of 5 mL. All injections were well tolerated, and no safety concerns were observed as summarized in the Online Table III .
Autologous MSCs Injections Reduce Scar Size and Improve the LV Ejection Fraction in Patients Undergoing CABG
Global MRI analyses in MSC-treated patients demonstrated an increased end-diastolic volume and decreased end-systolic volume at 18 months compared with baseline ( Figure 1 ). Increase in viable tissue correlated with the increase in LVEF (r=0.88, P=0.04; Figure 2A ). Scar size as a percentage of the total LV mass decreased in all patients (from 19.36±5.93% to 9.37±3.57% at 18 months, P=0.004), corresponding to a 53.64±5.4% decrease (P<0.0001).
MSCs Produce Significant Regional Improvements in Perfusion and Contractility
Next, we examined the impact of MSCs injection on regional scar mass, tissue perfusion, and regional contractility. We analyzed 384 segments from 6 patients at baseline, at 3, 6, and 18 months. Then, we identified segments that contained scar at baseline that received either only MSCs (by study design these segments were not revascularized; n=12), segments that represented territories that were only revascularized and not injected (n=63) and segments that were untreated (n=8). From the second group (revascularized only), we distinguished segments that were adjacent to the MSC-injected segments (n=16) and those that were remote (n=47; , P=0.03). Importantly, in MSC-injected segments, contractility (tissue tagging) and perfusion increased to a level similar to nonscarred segments at 18 months after treatment (Online Figure II) . There was a borderline improvement of systolic wall thickening in the revascularized only segments but no significant change in any of the rest of the metrics (perfusion, wall thickness, Ecc, and peak diastolic strain rate, Figure 3 ). In the untreated segments, no change was noted.
When the revascularized only segments were distinguished between those adjacent and those remote to the MSC injection sites, there was a uniform decrease of scar tissue both adjacently and remotely to the injection sites at 18 months (−55.01±15.16%, P=0.03 and −48.14±12.68%; P=0.0007 versus baseline, respectively). The improvement in systolic wall thickening (P=0.048, versus baseline) was noted preferentially 
Circulation Research
April 11, 2014
in revascularized segments adjacent to MSC injection sites (from 33.27±7.93% to 57.78±9.71%; P=0.04). The rest of the metrics remained unchanged in both subgroups.
Concordance Index Score Reveals the Extent of Action of MSCs Around the Injection Sites
We indexed the concordance of regional improvement in function, scar reduction, and tissue perfusion with a CIS. At 18 months, the injected only segments had a significantly greater CIS compared with revascularized-only and nontreated segments (2.93±0.07 versus 0.50±0.21 versus −0.07±0.34, respectively, P<0.0001). When segments were compared according to their proximity to the injection sites, we found that at 18 months, the injected nonrevascularized segments had a greater CIS than both the adjacent segments and remote segments (P<0.0001), and the segments adjacent to the site of MSC injection had a greater CIS compared with remote and nontreated segments (1.00±0.29 versus 0.42±0.30 versus −0.07±0.34, respectively, P=0.03; Figure 4 ).
Number of Cells Injected Correlates With the Decrease of Scar Size
Each patient received an average of 11±1.3 injections (range, 8-20 injections), and each injected segment received an average of 5.6±0.9 injections (range, 1-10 injections). There was a correlation between the number of cells injected in each segment and the observed decrease in segmental scar mass (r=0.6, P=0.04; Figure 2 ). A similar correlation was observed between the number of injections per segment and the reduction of scar size in that segment in the patients that received the highest dose of MSCs (r=0.74, P=0.04; Figure 2 ). The improvement in circumferential strain or perfusion did not correlate with the cell dose. Mesenchymal stem cell (MSCs) injections lead to regional improvement. A, Infarct size was decreased significantly at 3 months that was sustained at 6 and at 18 months in the injected only segments. In the revascularized only segments, the decrease of the infarct size became significant at 18 months. B, The average upslope corrected for the left ventricular blood pool intensity is a measure of regional perfusion. After MSCs injection, there was a significant increase of perfusion in the injected segments that differed significantly from the revascularized only segments. C, MSC injections led to a significant regional increase of wall thickness compared with the revascularized only segments. D, Systolic wall thickening improved in the injected segments and in the revascularized only segments. E, Peak Ecc is a measure of contractility with lower values signifying better contractility. There was significant improvement of peak Ecc at the injected segments over time and compared with revascularized only segments. F, Peak diastolic strain rate is an index of diastolic function and a higher value signifies improved diastolic function. There was a significant improvement in diastolic function at the injected segments compared with revascularized only. Figure 5 ).
Role of Collaterals in Perfusion
From data acquired during the patients' presurgery catheterizations and coronary angiograms, collateral vessels were visualized in 4 patients. To eliminate a major role 28, 29 of collateral circulation on the increase in tissue perfusion, we analyzed perfusions excluding 10 segments that contained scar at baseline (2 that were injected only, and 8 that were only revascularized). Perfusion increase was significantly different in the remaining 10 injected-only segments that were not perfused by collaterals, compared with the remaining 55 revascularized-only segments (36.6±13.6% versus 6.3±4.8%, respectively, P=0.04).
Discussion
Our study addresses the effects of autologous MSC injections in nonrevascularized infarcted areas of the left ventricle in patients with LV dysfunction undergoing CABG. We show that MSCs orchestrate a comprehensive improvement in scar reduction, tissue perfusion, and regional function that occurs predominantly at the site of MSC injection. These findings suggest that MSCs exert their benefits predominantly at a regional level, providing important guidance for the use of this strategy clinically. Additional phenotypic improvement, albeit to a lesser degree, occurs remotely, supporting the possibility of paracrine effects. 17, 30 Importantly in this study, the regional effects were of sufficient magnitude to drive a major increase in ejection fraction.
Our findings are in agreement with earlier studies of cell-based therapy in the setting of cardiac surgery, in which increases in LVEF 2 and perfusion, 3 decrease of scar tissue, 12 and increased wall motion and contractility 31 compared with patients undergoing only CABG are reported. Other studies, however, such as that of Hendrikx et al, 5 confirmed the safety of autologous bone marrow transplantation during CABG but did not demonstrate additional benefits beyond surgical revascularization. Taken together in totality, the aforementioned studies, although having different designs and using different cell populations, dosages, and delivery techniques, tended to show that bone marrow cell derivatives offer a benefit over that of CABG alone. In our study, we have shown that there was significant decrease of scar tissue, a corresponding increase in viable tissue and an increase in regional contractile performance (as measured by both systolic wall thickening and tissue tagging), which together yielded a significant increase of global LVEF. The seemingly paradoxical simultaneous increase in end-diastolic volume and LVEF, which is well described in other trials post-CABG, 24, 25, 32 is attributable to the interactions of an intact pericardium (or the lack thereof postsurgery) and the ventricular hemodynamics 33 without directly affecting the contractile performance. 32, 34 Our findings also agree and offer perspective on our previously published POSEIDON trial, 15 in which we also found a marked reduction in scar tissue in response to catheter delivery of autologous or allogeneic MSCs. In a subanalysis of POSEIDON, 35 scar tissue reduced in both the injected and the noninjected segments but the segmental EF was improved only in the injected segments. Interestingly in POSEIDON, we observed an increase in LVEF only in the group of patients receiving a low dose (20 mol/L) of MSCs. This effect is likely attributable to cell concentration rather than cell number, per se. The findings here of a dramatic increase in LVEF support this contention because the cell concentration was lower, and the delivery technique used here obviated the passage of a highly concentrated MSC suspension through the bore of the catheter. A significant decrease of scar size and an improvement in contractility (peak Ecc) at the site of injection were also observed in the Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT). 16 Importantly, both the POSEIDON and TAC-HFT trials document improvement in clinical outcomes (6-minute walk test and Minnesota Living with Heart Failure Questionnaire) in patients receiving intramyocardial cell therapy.
From preclinical and translational studies in an acute or subacute ischemic environment, it is known that MSCs act in a multifactorial manner. [36] [37] [38] [39] MSCs release antifibrotic matrix metaloproteases, modulate cardiac stem cell proliferation and differentiation, 9 stimulate neovascularization, 17, 22, 40 establish intercellular coupling with cardiomyocytes, 41 and mediate Akt-dependent change in calcium and upregulate Cx43. 42 All these mechanisms can explain scar reduction, improved perfusion, and contractility. In a recently published preclinical study 26 from our group, where allogeneic MSCs were used in a swine model of chronic ischemic LV dysfunction, infarct size reduction was the driving force of the reversal of remodeling that also led to an increase in LVEF.
The mechanism(s) of action of transplanted MSCs during CABG remain poorly delineated. In such a setting, 43, 44 the inflammation associated with an acute MI has subsided, fibrous tissue and remodeling have ensued, and the extent of hibernating myocardial tissue varies. All previous study designs targeted scarred areas that were revascularized, either by using the actual revascularized vessel or by injecting in the proximity of the revascularized region. The design of our study specifically targeted regions of scar that were not eligible for revascularization, thus enabling the study of differences in the behavior of scar that was either injected and not revascularized versus areas that were revascularized and did not receive MSCs. We acknowledge that there is an inherent limitation in the segmental Figure 5 . Topographical Analyses of MSC Injected Scarred Segments. A, Topographical analysis of a late contrast enhanced image that depicts scar (red color). The total endocardial length (white double headed arrow) of the scar was measured at baseline. The center of the scar on the endocardial border was then noted, and scar thickness was measured (distance from the endocardial contour to the distal border of the scar; yellow double headed arrows) at that point. The distance from the epicardial contour to the distal border of the scarred area was also measured at this point (Epicardial Cap; green double headed arrows). Then the same measurements were repeated at half the length from the lateral edges of the scar. The final values for each scar were derived by averaging the respective measurements. The same points were then identified at a slice in the same area at 18 months, and the calculations were repeated. B, At 18 months, the endocardial length decreased. C, Scar thickness also decreased at 18 months. D, There was also an increase in the epicardial cap thickness at 18 months. *P<0.05, paired t test.
by guest on December 23, 2017 http://circres.ahajournals.org/ Downloaded from analysis approach given that the segments of the heart are not insulated from one another. The use of MRI for the assessment of diastolic function still remains a controversial issue, 45 and criteria for MRI-derived diastolic function indices still need to be determined. Finally, the lack of a control group constitutes an important limitation to this study reducing the conclusiveness of our results. Nevertheless, these findings are hypothesis generating and can guide the design of future trials.
Despite these limitations, our data support that injected segments respond substantially better compared with the rest of the heart, despite the lack of regional revascularization. We also show a progressive drop-off in regional phenotypic improvement as distance from injection site increases. Together these findings are of important clinical value for designing and refining the strategy of incorporating cell-based therapy into surgical revascularization.
Conclusions
Together, these findings are consistent with the notion that MSCs act preferentially at the site of injection. In addition, there is a radius of action of the injected MSCs with a drop-off of activity as a function of distance from injection site. These findings coupled with the correlation of the number of injections and of the cells injected per segment with phenotypic outcome have mechanistic and therapeutic implications. Whereas cell dosing 15, 27 timing 46 of stem cell therapy and cell combination therapy 47 have been previously addressed, the present study illustrates the importance of the location and delivery method in the algorithm of achieving an optimal response to cell therapy in chronically scarred myocardium. Furthermore, using sophisticated imaging (MRI or CT) for identifying scarred areas coupled with a strategy to treat as much area of the scarred myocardium as possible is likely to contribute to the success of cell-based therapy.
Sources of Funding
This study was funded by the Specialized Center for Cell Therapeutics award (HL081028). Dr Hare is also supported by the National Institutes of Health grants: RO1 HL110737-01, R01 HL107110, R01 HL094849, CCTRN UM1 HL113460, and R01HL084275. Dr Karantalis is supported by an award from the American Heart Association.
Disclosures
Drs Hare and Heldman disclose a relationship with Vestion that includes equity, board membership, and consulting. Vestion did not contribute funding to this study. Dr Hare discloses equity in Kardia and a grant from Biocardia.
What Is Known?
• Bone marrow stem cells (MSCs) reduce infarct size, improve regional function, and contribute to reverse remodeling in ischemic cardiomyopathy.
• There are at least 3 dominant mechanisms underlying the improved cardiac phenotype after MSC administration: antifibrotic effects, neovascularization, and neomyogenesis.
• Accumulating clinical evidence support that MSC can accentuate cardiac structural and functional responses when delivered during CABG.
What New Information Does This Article Contribute?
• MSCs orchestrate a concordant improvement in cardiac structure by producing scar reduction, improved tissue perfusion and enhanced regional function with effects occurring predominantly at sites of cell injection.
• There is a progressive drop-off in regional phenotypic improvement as a function of distance from injection sites.
The use of sophisticated MRI imaging allows for the detailed identification of scarred areas facilitating the targeting of treatment sites as well as for noninvasive assessment of the mechanisms of action of MSCs in humans. This study used MRI imaging to independently assess regional changes in several important phenotypic parameters occurring in the ventricle in response to MSC injection. The study was designed to distinguish the effects of MSC injections from revascularization, per se, by selecting sites of injection as hypokinetic/akinetic segments that were not amenable for revascularization for clinical reasons. Our data show that injected segments respond substantially better compared with the rest of the heart, exhibiting scar reduction, increased tissue perfusion and increased regional function. We also show a progressive drop-off in regional phenotypic improvement as a function of distance from injection site. This study offers important insights into the mechanism of action of MSC therapy and provides novel guidance for cell injection strategies because future trials are planned for cell therapy for patients with ischemic heart disease. Factors considered in determining the areas of the myocardium suitable for revascularization, and those areas not suitable for intervention, during the CABG surgical procedure included (1) the size of the vessel at the site where insertion could technically be performed, (2) the location of that site, (3) the extent of disease distal to that site, (4) the viability of the territory being supplied by that vessel, (5) the availability of appropriate conduits, and (6) an assessment of the operative time the patient could tolerate.
Patient Population
Eligible patients had a diagnosis of chronic ischemic left ventricular dysfunction secondary to MI and were scheduled to undergo CABG. Additional criteria included age 21 to 80 years; LVEF between 20% and 50% by gated blood pool scan, two-dimension echocardiogram, cardiac MRI, or left ventriculogram within the prior six months not in the setting of a recent ischemic event; and had an akinetic/dyskinetic region by standard imaging. Exclusion criteria included a baseline glomerular filtration rate <50 ml/min/1.73m 2 , baseline hematocrit < 5%, serious radiographic contrast allergy, bone marrow dysfunction, as evidenced by a 20% or more deviation from normal white blood cell or platelet values without another explanation, coagulopathy condition, allergies to penicillin or streptomycin, contra-indication to performing an MRI scan, being an organ transplant recipient, malignancy within 5 years, a noncardiac condition that limited lifespan to <1 year, history drug or alcohol abuse within the past 24 months, on chronic therapy with immunosuppressant medication, and serum positive for HIV, hepatitis B surface antigen, or hepatitis C antibody.
Study Procedures and Timeline
Patients were screened approximately 7 weeks prior to CABG surgery. During the screening period and after written informed consent, patients underwent a battery of tests to ensure they met all inclusion and no exclusion criteria. Eligible patients returned for the bone marrow aspiration procedure approximately 4 to 5 weeks before surgery, providing enough time for harvesting and preparation of the MSCs. The injections were administered epicardially under direct visualization using a syringe and needle following the completion of the CABG procedure, and a detailed map of the locations and number of injections was recorded (Online Figure I) . The cells were injected into and surrounding an akinetic or severely hypokinetic territory not undergoing revascularization. Following the cardiac surgical procedure and the MSC injections, patients were followed at 3, 6 and 18 months.
Cardiovascular Magnetic Resonance Imaging Protocol
Contrast-enhanced MRI was performed at baseline and months 3, 6 and 18 post surgery. The imaging protocol included sagittal, axial and oblique scout images to localize the heart. Tissue tagging protocol for LVEF determination was performed prior to contrast administration to minimize tag line fading post-gadolinium. The protocol was based upon an ECG triggered fast gradient echo pulse sequence. Imaging parameters were: 36-40 cm field of view, 8 mm slice thickness, matrix size 256x128, TR=5.1msec, TE=1.4msec, flip angle=12°, and 8 phase-encoded views per frame. 
